• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Merit Medical Systems Inc. (Amendment)

    2/13/24 5:09:38 PM ET
    $MMSI
    Medical/Dental Instruments
    Health Care
    Get the next $MMSI alert in real time by email
    SC 13G/A 1 tv01441-meritmedicalsystemsi.htm SCHEDULE 13G/A meritmedicalsystemsinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 14)*

    Name of issuer:  Merit Medical Systems Inc

    Title of Class of Securities:  Common Stock

    CUSIP Number:  589889104

    Date of Event Which Requires Filing of this Statement: December 29, 2023

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  589889104

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    104,804

    7.  SOLE DISPOSITIVE POWER

    6,718,871

    8.  SHARED DISPOSITIVE POWER

    165,852

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    6,884,723

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    11.92%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Merit Medical Systems Inc

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    1600 West Merit Parkway
    South Jordan, UT 84095

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    589889104

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 13, 2024

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $MMSI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MMSI

    DatePrice TargetRatingAnalyst
    3/28/2025$120.00Overweight
    Analyst
    12/11/2024$103.00 → $120.00Equal Weight → Overweight
    Wells Fargo
    6/28/2024$96.00Outperform
    Robert W. Baird
    4/11/2024$88.00Buy
    CL King
    2/7/2024$87.00Neutral
    BofA Securities
    12/21/2023$100.00Hold → Buy
    Canaccord Genuity
    12/20/2022$73.00 → $72.00Buy → Hold
    Canaccord Genuity
    2/25/2022$73.00 → $72.00Outperform
    Raymond James
    More analyst ratings

    $MMSI
    Financials

    Live finance-specific insights

    See more
    • Merit Medical Reports First Quarter 2025 Results and Updates Full-Year Guidance

      First Quarter Highlights† Reported revenue of $355.4 million, up 9.8%Constant currency revenue* and constant currency revenue, organic* up 10.9% and up 6.0%, respectivelyGAAP operating margin of 11.5%, compared to 11.1% in prior year periodNon-GAAP operating margin* of 19.3%, compared to 17.0% in prior year periodGAAP EPS $0.49, up 2.0%Non-GAAP EPS* $0.86, up 14.8%Free cash flow* generation of $19.5 million, down 20.5% † Comparisons above are calculated for the current quarter compared with the first quarter of 2024, unless otherwise specified. Amounts stated in this release are rounded, while percentages are calculated from the underlying amounts. * Constant currency revenue; constant cu

      4/24/25 4:05:00 PM ET
      $MMSI
      Medical/Dental Instruments
      Health Care
    • Merit Medical Systems to Announce First Quarter 2025 Results on April 24, 2025

      SOUTH JORDAN, Utah, April 07, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will release its financial results for the quarter ended March 31, 2025, after the close of the stock market on Thursday, April 24, 2025. Merit plans to hold its investor conference call on the same day (Thursday, April 24, 2025) at 5:00 p.m. Eastern (4:00 p.m. Central, 3:00 p.m. Mountain, and 2:00 p.m. Pacific). To access the conference call, please pre-register using the following link. Registrants will receive confirmation with dial-in details. A live webcast and slide deck can be accessed us

      4/7/25 5:10:00 PM ET
      $MMSI
      Medical/Dental Instruments
      Health Care
    • Merit Medical Reports Fourth Quarter and Full Year 2024 Results and Issues Fiscal Year 2025 Guidance

      Fourth Quarter Highlights† Reported revenue of $355.2 million, up 9.4%Constant currency revenue* and constant currency revenue, organic* up 10.1% and up 6.1%, respectivelyGAAP operating margin of 10.3%, compared to 10.4% in prior year periodNon-GAAP operating margin* of 19.6%, compared to 16.6% in prior year periodGAAP EPS $0.46, down 2.6%,Non-GAAP EPS* $0.93, up 25.8%, andFree cash flow* generation of $65.3 million, up 18.4% Fiscal Year 2024 Highlights† Reported revenue of $1.357 billion, up 7.9%Constant currency revenue* and constant currency revenue, organic* up 8.5% and up 6.0%, respectivelyGAAP operating margin of 11.5 %, compared to 9.9% in prior yearNon-GAAP opera

      2/25/25 4:05:00 PM ET
      $MMSI
      Medical/Dental Instruments
      Health Care

    $MMSI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF OPERATING OFFICER Peterson Neil exercised 5,000 shares at a strike of $54.40 and sold $522,650 worth of shares (5,000 units at $104.53) (SEC Form 4)

      4 - MERIT MEDICAL SYSTEMS INC (0000856982) (Issuer)

      4/2/25 4:54:46 PM ET
      $MMSI
      Medical/Dental Instruments
      Health Care
    • CHIEF LEGAL OFFICER, SECRETARY Lloyd Brian G. gifted 4,700 shares, decreasing direct ownership by 12% to 34,245 units (SEC Form 4)

      4 - MERIT MEDICAL SYSTEMS INC (0000856982) (Issuer)

      3/14/25 11:45:46 AM ET
      $MMSI
      Medical/Dental Instruments
      Health Care
    • CHIEF HUMAN RESOURCES OFFICER Voigt Michel James gifted 620 shares, decreasing direct ownership by 3% to 21,779 units (SEC Form 4)

      4 - MERIT MEDICAL SYSTEMS INC (0000856982) (Issuer)

      3/6/25 5:41:11 PM ET
      $MMSI
      Medical/Dental Instruments
      Health Care

    $MMSI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Merit Medical Announces Health Canada Approval of the WRAPSODY® Cell-Impermeable Endoprosthesis

      The WRAPSODY CIE is designed to help physicians prolong functional vascular access in hemodialysis patients.Approval was supported by superior 12-month target lesion primary patency (70.1%) and access circuit primary patency (58.1%) in the randomized arm of the trial. SOUTH JORDAN, Utah, May 06, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a global leader of healthcare technology, announced today that the Wrapsody Cell-Impermeable Endoprosthesis (CIE) received regulatory approval from Health Canada. With this approval, Merit intends to begin immediate commercialization of the device throughout Canada with devices shipped from Merit's Toronto distribution center. Lo

      5/6/25 9:25:00 AM ET
      $MMSI
      Medical/Dental Instruments
      Health Care
    • Merit Medical Releases 12-Month Efficacy Results for the Single-Arm Arteriovenous Graft (AVG) Cohort of the WRAPSODY® Arteriovenous Efficacy (WAVE) Trial

      SOUTH JORDAN, Utah, May 05, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a global leader of healthcare technology, announced that the 12-month results from the single-arm cohort of the WAVE trial were presented at the annual Charing Cross Symposium held in London, England, on April 23, 2025, during the Vascular Access Masterclass session. Following the scientific podium presentation, results were presented during a Merit-sponsored symposium. The single-arm cohort of the WAVE trial included 112 patients with an AVG who were treated with the WRAPSODY CIE device. The primary efficacy measure, 6-month TLPP, was compared to an efficacy performance goal for covered stents

      5/5/25 9:25:00 AM ET
      $MMSI
      Medical/Dental Instruments
      Health Care
    • Merit Medical Reports First Quarter 2025 Results and Updates Full-Year Guidance

      First Quarter Highlights† Reported revenue of $355.4 million, up 9.8%Constant currency revenue* and constant currency revenue, organic* up 10.9% and up 6.0%, respectivelyGAAP operating margin of 11.5%, compared to 11.1% in prior year periodNon-GAAP operating margin* of 19.3%, compared to 17.0% in prior year periodGAAP EPS $0.49, up 2.0%Non-GAAP EPS* $0.86, up 14.8%Free cash flow* generation of $19.5 million, down 20.5% † Comparisons above are calculated for the current quarter compared with the first quarter of 2024, unless otherwise specified. Amounts stated in this release are rounded, while percentages are calculated from the underlying amounts. * Constant currency revenue; constant cu

      4/24/25 4:05:00 PM ET
      $MMSI
      Medical/Dental Instruments
      Health Care

    $MMSI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Merit Medical Systems Inc.

      SC 13G/A - MERIT MEDICAL SYSTEMS INC (0000856982) (Subject)

      11/14/24 11:05:03 AM ET
      $MMSI
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Merit Medical Systems Inc. (Amendment)

      SC 13G/A - MERIT MEDICAL SYSTEMS INC (0000856982) (Subject)

      2/13/24 5:09:38 PM ET
      $MMSI
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Merit Medical Systems Inc. (Amendment)

      SC 13G/A - MERIT MEDICAL SYSTEMS INC (0000856982) (Subject)

      2/12/24 5:32:43 PM ET
      $MMSI
      Medical/Dental Instruments
      Health Care

    $MMSI
    SEC Filings

    See more
    • SEC Form 10-Q filed by Merit Medical Systems Inc.

      10-Q - MERIT MEDICAL SYSTEMS INC (0000856982) (Filer)

      4/24/25 4:24:37 PM ET
      $MMSI
      Medical/Dental Instruments
      Health Care
    • Merit Medical Systems Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - MERIT MEDICAL SYSTEMS INC (0000856982) (Filer)

      4/24/25 4:20:47 PM ET
      $MMSI
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form 10-K/A filed by Merit Medical Systems Inc.

      10-K/A - MERIT MEDICAL SYSTEMS INC (0000856982) (Filer)

      4/14/25 4:08:28 PM ET
      $MMSI
      Medical/Dental Instruments
      Health Care

    $MMSI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $MMSI
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • Analyst initiated coverage on Merit Medical with a new price target

      Analyst initiated coverage of Merit Medical with a rating of Overweight and set a new price target of $120.00

      3/28/25 8:20:21 AM ET
      $MMSI
      Medical/Dental Instruments
      Health Care
    • Merit Medical upgraded by Wells Fargo with a new price target

      Wells Fargo upgraded Merit Medical from Equal Weight to Overweight and set a new price target of $120.00 from $103.00 previously

      12/11/24 7:56:29 AM ET
      $MMSI
      Medical/Dental Instruments
      Health Care
    • Robert W. Baird initiated coverage on Merit Medical with a new price target

      Robert W. Baird initiated coverage of Merit Medical with a rating of Outperform and set a new price target of $96.00

      6/28/24 8:04:44 AM ET
      $MMSI
      Medical/Dental Instruments
      Health Care
    • June 14, 2024 - FDA Roundup: June 14, 2024

      For Immediate Release: June 14, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA issued a proposed exemption for certain cottage cheese products from the requirements of the Food Traceability Rule. The proposal would exempt Grade “A” cottage cheese that appears on the Interstate Milk Shippers List from the requirements of the r

      6/14/24 3:54:45 PM ET
      $MMSI
      $BMY
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $MMSI
    Leadership Updates

    Live Leadership Updates

    See more
    • Merit Medical Announces Resignation of President, Joseph Wright

      SOUTH JORDAN, Utah, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI) ("Merit" or the "Company"), a global leader of healthcare technology, today announced the resignation of its President, Joseph C. Wright, effective January 3, 2025. The Company noted that prior to Mr. Wright's resignation, Merit had received notice of allegations regarding his conduct, which Merit's independent directors investigated with the assistance of independent counsel. The allegations were unrelated to Merit's operations or financial performance. Based upon Mr. Wright's resignation, Merit's Board of Directors has re-appointed Fred P. Lampropoulos as Merit's President. ABOUT MERI

      12/16/24 4:00:00 PM ET
      $MMSI
      Medical/Dental Instruments
      Health Care
    • Merit Medical Shareholders Elect Silvia M. Perez as New Director

      SOUTH JORDAN, Utah, May 16, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a global leader of healthcare technology, today announced that its shareholders elected Silvia M. Perez, President of the Commercial Branding and Transportation Division at 3M Company, as a director in Merit's Annual Meeting of Shareholders held on May 15, 2024. Merit's shareholders also re-elected Fred P. Lampropoulos and Stephen C. Evans as directors. Ms. Perez and Messrs. Lampropoulos and Evans were elected to serve three-year terms. "We are pleased to welcome Silvia Perez as our newest director," said Mr. Lampropoulos, Merit's Chairman and Chief Executive Officer. "Her expertise and proven

      5/16/24 4:05:00 PM ET
      $MMSI
      Medical/Dental Instruments
      Health Care
    • Merit Medical Executive Leadership Team Update

      Joe Wright Appointed President Expands Deep Bench of Leadership Team Talent; Supports "Continued Growth Initiatives" Program SOUTH JORDAN, Utah, May 15, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a global leader of healthcare technology, today announced the appointment of Joe Wright as President, effective immediately. As President, Mr. Wright will be responsible for the oversight of Merit's global commercial, marketing, and manufacturing operations. Mr. Wright has been an instrumental part of the Merit team over the past 19 years. He most recently served as Chief Commercial Officer, where he led the development and expansion of Merit's global commercial activit

      5/15/24 4:05:00 PM ET
      $MMSI
      Medical/Dental Instruments
      Health Care